Kansas Medicaid spending on GLP-1 drugs

How much did Kansas Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $53.6 million for GLP-1 drugs paid through Kansas Medicaid in 2025, across at least 50,903 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 36 rows of 161, so these figures are floors.

Pharmacies were reimbursed at least $9.5 million for GLP-1 drugs paid through Kansas Medicaid in 2026 (quarter 1 only, as posted so far), across at least 8,638 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 15 rows of 42, so these figures are floors.

By year and ingredient

2020at least $400,449No dataat least $5,317,140at least $1,022,380at least $816,991$86,158$51,372at least $7,694,490
2021at least $697,716No data$5,569,756at least $3,958,102at least $238,732$111,564Suppressedat least $10,575,871
2022at least $2,924,340at least $119,463$6,055,662at least $6,863,565at least $90,232$146,976Suppressedat least $16,200,237
2023at least $13,341,489at least $2,407,549$5,299,873at least $8,504,809at least $39,042$138,406Suppressedat least $29,731,167
2024at least $11,387,620at least $14,088,006at least $938,100at least $4,126,909at least $19,305$73,702Suppressedat least $30,633,642
2025at least $14,758,061at least $35,926,426at least $367,041at least $2,483,864Suppressed$37,710Suppressedat least $53,573,102
2026 (Q1)at least $3,029,383at least $6,155,946at least $24,229at least $285,629No dataSuppressedSuppressedat least $9,495,187

By product, 2025

Ozempicat least $6,829,147at least 7,0961 of 13
Rybelsusat least $145,108at least 1534 of 12
Wegovy$7,783,8066,0220 of 20
Mounjaroat least $7,740,864at least 7,4551 of 25
Zepboundat least $28,185,562at least 26,9599 of 33
Liraglutide (generic name listing)at least $194,149at least 36811 of 25
Saxendaat least $172,892at least 1461 of 4
VictozaSuppressedSuppressed2 of 2
Trulicityat least $2,483,864at least 2,6512 of 18
BydureonSuppressedSuppressed1 of 1
Soliqua$37,710530 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $11,160,637at least 10,9098 of 40
Q2 2025at least $13,103,674at least 12,6137 of 38
Q3 2025at least $14,076,965at least 13,2439 of 40
Q4 2025at least $15,231,825at least 14,13812 of 43

By quarter, 2026 (posted so far)

Q1 2026at least $9,495,187at least 8,63815 of 42

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.